UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 44

Sortiert nach

Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia

The American journal of psychiatry, 2008-08, Vol.165 (8), p.1033-1039

2008

Link zum Volltext

Verfügbarkeit prüfen

Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat

Neuropharmacology, 2006-05, Vol.50 (6), p.755-760

2006

Link zum Volltext

Verfügbarkeit prüfen

Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: Implications for treatment of attention-deficit hyperactivity disorder

Synapse (New York, N.Y.), 2012-06, Vol.66 (6), p.522-532

2012

Link zum Volltext

Verfügbarkeit prüfen

Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor

The Journal of pharmacology and experimental therapeutics, 2002-06, Vol.301 (3), p.1020

2002

Link zum Volltext

Verfügbarkeit prüfen

Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine

Neuropsychopharmacology (New York, N.Y.), 1996-02, Vol.14 (2), p.87-96

1996

Link zum Volltext

Verfügbarkeit prüfen

Effects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activity

Synapse (New York, N.Y.), 2012-05, Vol.66 (5), p.435-444

2012

Link zum Volltext

Verfügbarkeit prüfen

Atomoxetine Increases Extracellular Levels of Norepinephrine and Dopamine in Prefrontal Cortex of Rat: A Potential Mechanism for Efficacy in Attention Deficit/Hyperactivity Disorder

Neuropsychopharmacology (New York, N.Y.), 2002-11, Vol.27 (5), p.699-711

2002

Link zum Volltext

Verfügbarkeit prüfen

Brain region and dose effects of an olanzapine/fluoxetine combination on extracellular monoamine concentrations in the rat

Neuropharmacology, 2004-02, Vol.46 (2), p.232-242

2004

Link zum Volltext

Verfügbarkeit prüfen

Duloxetine Increases Serotonin and Norepinephrine Availability in Healthy Subjects: A Double-Blind, Controlled Study

Neuropsychopharmacology, 2003-09, Vol.28 (9), p.1685-1693

2003

Link zum Volltext

Verfügbarkeit prüfen

Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine Transporters in vitro and in vivo, Human Serotonin Receptor Subtypes, and Other Neuronal Receptors

Neuropsychopharmacology (New York, N.Y.), 2001-12, Vol.25 (6), p.871-880

2001

Link zum Volltext

Verfügbarkeit prüfen

Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex

Psychopharmacologia, 2002-04, Vol.160 (4), p.353-361

2002

Link zum Volltext

Verfügbarkeit prüfen

Synergistic Effects of Olanzapine and Other Antipsychotic Agents in Combination with Fluoxetine on Norepinephrine and Dopamine Release in Rat Prefrontal Cortex

Neuropsychopharmacology (New York, N.Y.), 2000-09, Vol.23 (3), p.250-262

2000

Link zum Volltext

Verfügbarkeit prüfen

R-fluoxetine Increases Extracellular DA, NE, As Well As 5-HT in Rat Prefrontal Cortex and Hypothalamus: An in vivo Microdialysis and Receptor Binding Study

Neuropsychopharmacology (New York, N.Y.), 2002-12, Vol.27 (6), p.949-959

2002

Link zum Volltext

Verfügbarkeit prüfen

Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiles

Circulation (New York, N.Y.), 2004-06, Vol.109 (25), p.3202-3207

2004

Link zum Volltext

Verfügbarkeit prüfen

Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats

Neuropharmacology, 2003-12, Vol.45 (7), p.935-944

2003

Link zum Volltext

Verfügbarkeit prüfen

Amantadine for weight gain associated with olanzapine treatment

European neuropsychopharmacology, 2005, Vol.15 (1), p.13-21

2005

Link zum Volltext

Verfügbarkeit prüfen

M1 muscarinic receptor signaling in mouse hippocampus and cortex

Brain research, 2002-07, Vol.944 (1), p.82-89

2002

Link zum Volltext

Verfügbarkeit prüfen

Elucidating the role of muscarinic receptors in psychosis

Life sciences (1973), 2001-04, Vol.68 (22), p.2605-2613

2001

Link zum Volltext

Verfügbarkeit prüfen

Treatment of glossodynia with olanzapine

Journal of the American Academy of Dermatology, 2004-09, Vol.51 (3), p.463-465

2004

Link zum Volltext

Verfügbarkeit prüfen

LY248686, a new inhibitor of serotonin and norepinephrine uptake

Neuropsychopharmacology (New York, N.Y.), 1993, Vol.8 (1), p.23-33

1993

Link zum Volltext

Verfügbarkeit prüfen

The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex

Biological psychiatry (1969), 2001-04, Vol.49 (8), p.716-725

2001

Link zum Volltext

Verfügbarkeit prüfen

Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats

The Journal of pharmacology and experimental therapeutics, 1999-08, Vol.290 (2), p.901

1999

Link zum Volltext

Verfügbarkeit prüfen

The muscarinic receptor agonist BuTAC, a novel potential antipsychotic, does not impair learning and memory in mouse passive avoidance

Schizophrenia research, 2001-04, Vol.49 (1), p.193-201

2001

Link zum Volltext

Verfügbarkeit prüfen

Muscarinic receptor agonists decrease cocaine self-administration rates in drug-naive mice

European journal of pharmacology, 2000-08, Vol.402 (3), p.241-246

2000

Link zum Volltext

Verfügbarkeit prüfen

Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5 R,6 R)6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane

European journal of pharmacology, 1998-09, Vol.356 (2), p.109-119

1998

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 44

Suche als RSS-Feed

Aktive Filter

ThemaLife Sciences & Biomedicine

ThemaMale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(42)
Mit Volltextzugriff
(38)

Publikationsform

Artikel
(44)

Sprache

Englisch
(44)
Japanisch
(13)

Erscheinungsjahr

n.n

Thema

Science & Technology
(44)
Animals
(38)
Pharmacology & Pharmacy
(30)
Rats
(29)
Biological And Medical Sciences
(27)
Neurosciences & Neurology
(23)
Neurosciences
(22)
Medical Sciences
(21)
Pharmacology. Drug Treatments
(18)
Neuropharmacology
(16)
Dose-Response Relationship, Drug
(15)
Psychology. Psychoanalysis. Psychiatry
(15)
Rats, Sprague-Dawley
(15)
Humans
(13)
Mice
(13)
Psychiatry
(13)
Psychopharmacology
(13)
Norepinephrine - Metabolism
(11)

13 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia

Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat

Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: Implications for treatment of attention-deficit hyperactivity disorder

Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor

Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine

Effects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activity

Atomoxetine Increases Extracellular Levels of Norepinephrine and Dopamine in Prefrontal Cortex of Rat: A Potential Mechanism for Efficacy in Attention Deficit/Hyperactivity Disorder

Brain region and dose effects of an olanzapine/fluoxetine combination on extracellular monoamine concentrations in the rat

Duloxetine Increases Serotonin and Norepinephrine Availability in Healthy Subjects: A Double-Blind, Controlled Study

Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine Transporters in vitro and in vivo, Human Serotonin Receptor Subtypes, and Other Neuronal Receptors

Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex

Synergistic Effects of Olanzapine and Other Antipsychotic Agents in Combination with Fluoxetine on Norepinephrine and Dopamine Release in Rat Prefrontal Cortex

R-fluoxetine Increases Extracellular DA, NE, As Well As 5-HT in Rat Prefrontal Cortex and Hypothalamus: An in vivo Microdialysis and Receptor Binding Study

Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiles

Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats

Amantadine for weight gain associated with olanzapine treatment

M1 muscarinic receptor signaling in mouse hippocampus and cortex

Elucidating the role of muscarinic receptors in psychosis

Treatment of glossodynia with olanzapine

LY248686, a new inhibitor of serotonin and norepinephrine uptake

The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex

Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats

The muscarinic receptor agonist BuTAC, a novel potential antipsychotic, does not impair learning and memory in mouse passive avoidance

Muscarinic receptor agonists decrease cocaine self-administration rates in drug-naive mice

Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5 R,6 R)6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane

Aktive Filter

Suchergebnisse filtern